Please assess the completion status of the following clinical trial:

Trial Title: Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Informed subject consent will be obtained from those patients meeting the following inclusion criteria:~* Male and female patients 18 years or older.~* Clinical and/or histopathological diagnosis of PRP~* Candidate for systemic therapy (PASI ≥ 10)~* Body surface area of involvement ≥ 10%~* Good general health as confirmed by medical history~* Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and~* Patients who read and sign an approved informed consent for this study~Exclusion Criteria~Patients are to be excluded based on the following criteria:~* Vulnerable study population~* Pregnant or nursing women~* Women planning a pregnancy within the study period~* Human immunodeficiency virus (HIV) positivity~* Known history of adverse reaction to Cosentyx~* Known history of hepatitis B, hepatitis C, or tuberculosis~* Personal or family history of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Patients with a biopsy proven diagnosis of PRP

Based on this trial design, predict the completion outcome and termination type (if applicable).